Starting in 2021, Medicare patients could have access to a new permanent home infusion benefit. The Center for Medicare &amp; Medicaid Services (CMS) proposed the benefit in July as part of <a href="https://homehealthcarenews.com/2019/07/cms-proposes-elimination-of-raps-250-million-medicare-payment-increase/">its proposed home health payment rule</a>, with the goal being to move more care into the home.While some view the proposed benefit as a win and an opportunity creator for home health care companies, others argue the benefit is &ldquo;deeply flawed&rdquo; and doesn&rsquo;t go far enough.Home infusion is the at-home delivery of a drug directly into a patient&rsquo;s vein through a needle or catheter. Currently, Medicare only offers home infusion benefits to certain patients.<figure><a href="https://servedbyadbutler.com/redirect.spark?MID=166549&plid=1007911&setID=335899&channelID=0&CID=279667&banID=519756400&PID=0&textadID=0&tc=1&mt=1567980739572479&sw=1024&sh=768&spr=1&hc=afbad17cca1767e6e930052500f787dc75006573&location="><img alt="" src="https://media-aws02.inloop.com/ins1/19a/9d94892fff82412dbfdeb2d4095b6e2a-contentimage?size=large" class=" aggr-main-image" /></a></figure>While Congress passed the 21st Century Cures Act in 2016 to offer a home infusion benefit, the start of those benefits was delayed until 2021. On top of that, reimbursement changes in recent years have made it difficult for patients already receiving Medicare-covered home infusions to afford the services.However, the aim of this proposed benefit, which would take effect in 2021, is to change that, giving the patients the choice to receive care in their homes.&ldquo;We are proud to announce the new permanent home infusion therapy benefit that will give patients the freedom to safely access critical treatments, such as chemotherapy, at home instead of traveling to the hospital or doctor&rsquo;s office, improving their quality of life,&rdquo; CMS Administrator Seema Verma said in a press release following the proposed rule&rsquo;s release.In addition to chemotherapy, other examples of home infusion include immune deficiency and anti-infective treatment. All three would be Medicare-reimbursable if the home infusion benefit takes effect.&ldquo;This is fantastic,&rdquo; Laizer Kornwasser, President and COO of CareCentrix, told Home Health Care News. &ldquo;We believe that patients want to be treated in the home when they&rsquo;re able to. This allows for patients to be treated in the home. It&rsquo;s a win-win for patients, and it provides tremendous opportunity for [home health] providers.&rdquo;Hartford, Connecticut-based CareCentrix is a post-acute and home health care solutions company that works with a network of providers to help ensure patients get the right services at the right time, in the right location. The company also takes on readmissions risk for post-acute care providers a full 90-days post-discharge, Kornwasser said.Overall, he says CareCentrix&rsquo;s home health clients are excited about the prospect of delivering home infusion using the proposed benefit in the years to come.&ldquo;From what I&rsquo;ve heard, people are embracing the fact that this will open up more volume coming to the home, and it will create opportunity,&rdquo; Kornwasser said.While many logistics surrounding how the proposed benefit will work remain unclear, CMS has proposed breaking home infusion medications down into three payment categories, in addition to paying higher reimbursements for initial home infusion visits, while slightly decreasing reimbursements to follow.On top of creating opportunities for home health providers, the benefit could also mean a huge cost savings for Medicare. The Congressional Budget Office previously estimated that a home infusion benefit could reduce Medicare spending by $372 million through 2026.&ldquo;As you move care into the home, costs go down,&rdquo; Kornwasser said. &ldquo;You&rsquo;re not paying all the fees that are associated with hospital settings. You&rsquo;re not paying for transportation. [And] you&rsquo;re also increasing compliance with therapy treatment by making it more convenient for the patient.&rdquo;<h3>&lsquo;Deep Flaws&rsquo; </h3>Not everyone is sold on the idea that the proposed benefit will be able to move a large number of Medicaid-covered infusion patients into the home.Take Option Care Health Chief Strategy Officer Richard Denness, for example.&ldquo;The proposed CMS rule is deeply flawed because it limits reimbursement for home infusion services to just the days when a nurse is present in the patient&rsquo;s home,&rdquo; Denness told HHCN. &ldquo;The proposed rule does not reflect the reality of how most patients receive home infusion therapy.&rdquo;Bannockburn, Illinois-based Option Care is one of the largest home infusion providers in the country, serving patients in all 50 states and delivering more than 2 million home infusion doses each month across all therapy areas.Denness says the proposed benefit misunderstands and devalues all the elements that go into home infusion, leaving the cost of the service still largely out of reach.&ldquo;For most patients, a nurse is only present once per week, and home infusion therapy is coordinated by specialty pharmacists who design the therapy in coordination with a patient&rsquo;s physician, assess the patient, monitor for adverse drug reactions, coordinate care with a care team and make modifications to the plan of care as necessary,&rdquo; he said.Without access to reimbursement for professional services, home infusion can be unaffordable for Medicare patients, Denness said.As such, Option Care continues to work with other members of the National Home Infusion Association (NHIA) to advocate for improved reimbursement from CMS.&ldquo;Any patient that is a candidate for home infusion should have that option, and we&rsquo;re working to help make that possible,&rdquo; Denness said.CMS is accepting comments on the proposed rule, which includes the permanent home infusion benefit, through September 9.

Starting in 2021, Medicare patients could have access to a new permanent home infusion benefit. The Center for Medicare & Medicaid Services (CMS) proposed the benefit in July as part of its proposed home health payment rule, with the goal being to move more care into the home.
While some view the proposed benefit as a win and an opportunity creator...

Proposed Home Infusion Benefit Exciting to Some, ‘Deeply Flawed' to Others

Key takeaways:
Although banned in hand soaps, some consumer goods still include triclosan.
Rises in childhood urinary triclosan concentration were met with a heightened risk for eczema and allergic rhinitis symptoms.
As the urinary concentration of triclosan during childhood went up, so did a child’s risk for eczema and allergic rhinitis, according

Childhood exposure to antimicrobial linked to elevated risk for eczema, allergic rhinitis

In an interview with OncLive®, Qian (Janie) Qin, MD, highlighted the importance of early somatic and germline testing to inform subsequent treatment decisions for patients who with metastatic hormone-sensistive prostate cancer (mHSPC) who develop metastatic castration-resistant prostate cancer (mCRPC); reviewed pivotal trials supporting PARP inhibi

HARMONY Study Aims to Personalize PARP Inhibition in mHSPC Through Adaptive Design, Diverse Patient Enrollment

WhiteBlackRedGreenBlueYellowMagentaCyanOpaqueSemi-TransparentBlackWhiteRedGreenBlueYellowMagentaCyanOpaqueSemi-TransparentTransparentBlackWhiteRedGreenBlueYellowMagentaCyanTransparentSemi-TransparentOpaque
50%75%100%125%150%175%200%300%400%NoneRaisedDepressedUniformDropshadowProportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace Ser

Real-World Data of SOC Cilta-Cel in R/R MM and Cilta-Cel in Patients With High-Risk Features

First-line treatment with the combination of osimertinib (Tagrisso) in combination with chemotherapy led to a statistically significant and clinically meaningful improvement in overall survival (OS) compared with osimertinib alone in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations, according

First-Line Osimertinib Plus Chemo Boosts OS in EGFR+ NSCLC

KRAS G12C mutations may be associated with a poorer prognosis with standard first-line chemotherapy regimens for patients with metastatic colorectal cancer (mCRC), according to Cathy Eng, MD.
In a poster presentation at the 2025 ESMO Gastrointestinal Cancers Congress, Eng and colleagues shared results from a retrospective real-world analysis evalua

Real-World Analysis Highlights Potential Prognostic Impact of KRAS G12C Mutations in First-Line mCRC

Intravitreal ceftazidime may help treat syphilitic uveitis when IV penicillin is delayed.
Ceftazidime is not a substitute for IV penicillin, which is the preferred treatment.
A case series reported that 14 eyes showed improved inflammation with nine eyes gaining an average of 5.4 lines of vision.
Intravitreal injections with the antibiotic ceftazid

When Systemic Therapy Is Delayed for Syphilitic Uveitis, Ceftazidime May Help

A new Guillain-Barré syndrome mimic that appeared to be triggered by mild infection emerged in children with biallelic RCC1 variants, a case series showed.
One of the first cases was seen in a previously fit and well 7-month-old British Pakistani girl who presented with a rapid onset of ascending flaccid paralysis with areflexia following a fever a

Novel Guillain-Barre Mimic Emerges in Kids With Certain Gene Variants

Aluminum-adsorbed vaccines not tied to chronic diseases in kids, large study shows
Aluminum-adsorbed vaccines were not associated with the development of chronic diseases in youth, according to a large study published in Annals of Internal Medicine.
Common cold incidence decreased by more than 50% during pandemic
FDA approves simplified prefilled s

Vaccination

The FDA recently approved gepotidacin oral tablets (Blujepa; GSK) for the treatment of uncomplicated urinary tract infections (UTIs) caused by Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus, and Enterococcus faecalis in girls and women 12 years and older who weigh at least 40 kg. The approval als

Blujepa From GSK

Key Takeaways
The INDEPENDENCE trial did not achieve its primary endpoint of RBC transfusion independence over 12 weeks, but showed clinically meaningful improvements in secondary endpoints.
Luspatercept demonstrated a reduction in transfusion burden and an increase in hemoglobin levels, suggesting potential benefits for myelofibrosis-associated an

Luspatercept Plus Concomitant JAK Inhibitor Therapy Misses Primary End Point in Myelofibrosis-Associated Anemia

HealthDay News — Slightly higher levels of cardiac biomarkers may predict an increased risk for incident cancer, according to a study published online in the July issue of JACC: Advances.
Xinjiang Cai, M.D., Ph.D., from the University of California, Los Angeles, and colleagues examined the association between baseline levels of high-sensitivity car

Higher Cardiac Marker Levels Tied to Long-Term Cancer Risk

A global clinical trial has been launched to evaluate the oral therapy candidate BMS-986368 for treating spasticity — muscle stiffness and spasms — in people with multiple sclerosis (MS).
The Phase 2 study (NCT06782490), called BALANCE-MSS-1, will enroll about 200 adults with MS who have experienced spasticity for at least six months. The planned t

New global trial testing oral therapy BMS-986368 for MS spasticity

Although nirmatrelvir-ritonavir and molnupiravir have been linked to reduced risk for severe COVID-19 progression in outpatient settings, neither antiviral improved clinical outcomes for hospitalized patients when combined with usual care.
The addition of molnupiravir or nirmatrelvir-ritonavir to usual care was not associated with improvements in c

Molnupiravir, Nirmatrelvir-Ritonavir Not Supported for Inpatients With COVID-19

Treatment with belzutifan (Welireg) demonstrated a clinically meaningful and statistically significant improvement in quality-adjusted survival time vs everolimus (Afinitor) among patients with advanced renal cell carcinoma (RCC), according to findings from a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of the phase 3 LITES

Belzutifan Improves Quality-Adjusted Survival Time in Advanced RCC

Following the irradiation, the median size of the spleen of the patients went from 25 cm down to 22 cm, which was a significant reduction.
A low-dose splenic irradiation protocol before hematopoietic stem cell transplantation (HSCT) led to a substantial reduction in spleen size in patients with myelofibrosis (MF) while having favorable engraftment

Low-Dose Splenic Irradiation Before HSCT Safe and Effective in MF

The FDA's CRL for glofitamab with GemOx in relapsed/refractory DLBCL was due to insufficient evidence from the STARGLO trial for U.S. approval.
STARGLO trial showed promising ORR and OS results for glofitamab, but safety concerns included higher adverse event rates compared to rituximab.
The FDA has issued a complete response letter (CRL) to the su

FDA Issues CRL for Glofitamab Plus Chemo in R/R DLBCL

From 2019 to 2024, the annual number of publications related to AI in nursing decision-making increased from 8 to 60.
Research on artificial intelligence (AI) and its role in nursing decision-making are growing rapidly, with certain nations emerging as leaders. These findings were recently published in Nursing Reports.
Researchers conducted a syste

Research on AI in Nursing Decision-Making Grows, Globalizes, and Evolves

Contact

Advertise

Other industries

Empower vascular access teams with tools that streamline workflows, enhance teamwork, and improve outcomes.

Tools for Efficient Vascular Access | Salubrity Online

Gebauer’s Pain Ease® works in just 4-10 seconds!

Give patients the comfort they deserve

Ivenix Infusion System

You have several options—but you also have several reasons to choose one above the rest.
Learn more now.


Prescribing IVIg?

AVA Consensus Statement recommend adhesives like gum mastic to secure PIVC dressings and devices.